Theseus Pharma EGFR compound Cmpd A

Theseus Pharma EGFR compound Cmpd A: sourced facts only. name: "A representative member from this series (Cmpd A) potently inhibits the kinase activity of EGFR L, LT, and LTC variants with IC50s ≤0.2 nM, compared to IC50s for osimertinib of 0.4, 0.2, and 360 nM respectively." [DOI:10.1158/1538-7445.am2022-3342]; target: "A representative member from this series (Cmpd A) potently inhibits the kinase activity of EGFR L, LT, and LTC variants with IC50s ≤0.2 nM, compared to IC50s for osimertinib of 0.4, 0.2, and 360 nM respectively." [DOI:10.1158/1538-7445.am2022-3342]; developer: "1Theseus Pharmaceuticals, Inc., Cambridge, MA." [DOI:10.1158/1538-7445.am2022-3342]; stage: "In vivo, Cmpd A (30 mg/kg QD) induced tumor regression, or inhibited tumor growth by at least 90%, in models containing EGFR single (L), double (LT), and triple (LTC and DTC) mutant variants." [DOI:10.1158/1538-7445.am2022-3342]